Want to join the conversation?
$XRAY's net acquisition growth rate was 0.3% negative in 3Q15 primarily reflecting the impact of small divestitures of non-core products that more than offset the impact from acquisitions. The impact of discontinued products reduced the internal growth rate by about 50 basis points in 3Q15.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.